OnKure Therapeutics (OKUR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on the stock and has a $20.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sam Slutsky’s rating is based on OnKure Therapeutics’ strategic decision to delay the nomination of their pan-mutant selective PI3Ka inhibitor development candidate to the second half of 2025. This delay is attributed to the company’s thorough analysis of multiple promising candidates, aiming to select a molecule with high selectivity over wild type, which is crucial for addressing investor concerns about the efficacy of current clinical ‘pan-mutant’ PI3Ka inhibitors.
Furthermore, OnKure’s management has expressed confidence in the preclinical results of their pan-mutant molecules, indicating a strong potential for success. The company’s focus on achieving approximately 10-fold selectivity against common PI3Kα mutations over wild type demonstrates their commitment to developing a highly effective treatment, which supports the Buy rating given by Sam Slutsky.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is neutral on the stock.